Development

Editor of Pharmaceutical Technology Europe

Articles

Accelerated formulation strategies are a useful tool to reduce development timelines and cost, but key priorities must be considered early on to ensure success.

Focusing on Accelerated Formulation Strategies

Aaron Stewart is associate principal scientist at Lonza Pharma and Biotech, Bend, OR.

In-vitro and in-silico tools can help predict in-vivo outcomes for low-solubility drugs formulated as spray-dried dispersions. 

Advancing Spray-Dried Dispersion Formulation Development

Hovione has successfully completed the Phase II clinical trial of its ophthalmic formulation of minocycline, Meizuvo.

Hovione Successfully Completes Phase II Trial of Minocycline Ophthalmic

Various strategies to improve bioavailability are being continuously evaluated, affording greater commercial prospects for the future.

Reviewing Recent Bioavailability Research

FDA moves recommended timeline for API and drug manufacturers to assess impurity risks to March 31, 2021.

Nitrosamine Risk Assessment Date Extended

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Plasma-based proteins and cell-based therapies have significant potential to address unmet medical needs.

Exploring the Therapeutic Value of Blood Components

Rapid growth in biologics and increasing complexity of new compounds are some of the factors driving development of innovative delivery solutions.

Developments Driving Drug Delivery

Jennifer Putnam is AR&D supervisor II, Perrigo

Katherine L. Ullman is president, KLU Consulting, LLC

Priscilla Zawislak is global regulatory affairs advocacy manager, DuPont Nutrition & Biosciences

David Schoneker is president, Black Diamond Regulatory Consulting, LLC

George Collins is vice president, Vanderbilt Chemicals LLC. 

Douglas G. Muse is consultant—Compendial Affairs, Eli Lilly & Co.

Brian Carlin is director QbD/Regulatory, DFE Pharma US

Joseph Zeleznik is technical product manager, IMCD US

R. Christian Moreton, PhD, is vice-president of pharmaceutical sciences at Finnbrit Consulting and a member of Pharmaceutical Technology’s editorial advisory board.

Viewpoint: Continued dialogue among pharma stakeholders is needed to achieve consensus regarding excipient composition.


Understanding Concomitant Components in Pharmaceutical Excipients

The right partner can help companies overcome key formulation challenges for biologic drugs.

Overcoming Biologic Drug Formulation Hurdles

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.